IPOSchedule
EN
EnglishDeutschFrançais
2026 offering

BIOVENTRIX IPO

BIOVENTRIX develops, manufactures and commercializes medical devices intended to restore left ventricular function in patients with heart failure and reduced ejection fraction.

  • BVXX
  • Nasdaq Capital Market
  • United States
  • Healthcare
Withdrawn offering · 14 Oct 2026

This offering did not proceed. Proposed terms and company information are preserved from this IPO attempt.

Last verified 19 Oct 2026

Company overview

BIOVENTRIX website

BIOVENTRIX is a medical device company focused on proprietary devices for patients with heart failure and reduced ejection fraction. Its activities include developing, manufacturing and commercializing these devices.

Company country
United States

Offering details

Base offering, before overallotment

Exchange
Nasdaq Capital Market
Ticker
BVXX

IPO timeline

  1. Registration filed
  2. Proposed terms published
  3. Offering withdrawn

Filings and documents

Other IPO profiles

Industrials01

VME Companies

VME Companies provides engineering, procurement and construction services and modular process systems and equipment.

IPO valuation$276M – $345M
Filings Nasdaq Capital MarketIPO
Industrials02

Helio Corp /FL/

Helio Corporation is a holding company providing technology, engineering, and research and development services.

Listing valuation$29.5M – $36.8M
Filings Nasdaq Capital MarketUplisting
Healthcare03

Neuro Spectrum Insights

Neuro Spectrum Insights develops software to support autism diagnosis through MRI image analysis.

IPO valuation$60.4M – $75.4M
Filings NYSE AmericanIPO